Renewal of Agreement

RNS Number : 7176G

Alliance Pharma PLC

17 May 2011

 



For immediate release

17 May 2011

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Renewal of ImmuCyst Distribution Agreement

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce the renewal for a period of up to seven years of its agreement with sanofi pasteur, the vaccines division of Sanofi, for the distribution of ImmuCyst^® in the UK and Ireland.

ImmuCyst is a treatment for non-muscle-invasive bladder cancer.  Sales of the product in the twelve months ended 30 April 2011 in the UK and Ireland were £3.7 million.  ImmuCyst has been distributed by Alliance's Cambridge Laboratories business unit since the acquisition of the trade and certain assets of Cambridge Laboratories in February 2010.  The renewal of the ImmuCyst distribution agreement triggers the payment by Alliance of up to £2.1 million deferred cash consideration for Cambridge Laboratories.

Commenting on the renewal, John Dawson, Chief Executive, said:"I am delighted that sanofi pasteur has demonstrated its continued confidence in the work of the Cambridge Laboratories business unit.  We will aim to reward that confidence with further success from this cornerstone of our oncology portfolio during the coming years."

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Jessica Fontaine
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Simon Blank
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections.  Alliance's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

 

END

 

 

AGREASSXFSXFEEF